Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized, controlled, pilot clinical study in patients with
COVID-19, to obtain preliminary biologic, physiologic, and clinical data in patients with
COVID-19 treated with rhACE2 or control patients, to help determine whether a subsequent
Phase 2B trial is warranted.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University